Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.3% – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) dropped 2.3% during mid-day trading on Friday . The company traded as low as $1,178.32 and last traded at $1,189.0620. 1,978,736 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 3,205,755 shares. The stock had previously closed at $1,216.95.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and reiterated a buy rating, signaling confidence in further upside from current levels. Benzinga article
• Positive Sentiment: JPMorgan and RBC also reportedly lifted their LLY targets, reinforcing Wall Street’s bullish stance on Lilly’s growth outlook and drug demand. TheStreet article
• Positive Sentiment: New coverage highlighted record GLP-1 usage and accelerating sales of Lilly’s best-selling obesity and diabetes medicines, supporting expectations for strong revenue growth. Motley Fool article
• Positive Sentiment: Lilly announced progress in its neuropathic pain program, with a Phase 2 trial reaching completion, adding to the company’s pipeline momentum beyond GLP-1 drugs. TipRanks article
• Positive Sentiment: Lilly said it will present 16 abstracts at AAIC 2026, including new Alzheimer’s diagnostic and therapeutic data, which could broaden investor confidence in its longer-term growth pipeline. PR Newswire article
• Neutral Sentiment: Several market commentary pieces noted that biotech and Lilly remain among the market’s stronger growth names, with mutual funds and strategists showing continued interest in the sector. Zacks article
• Negative Sentiment: Tampa General Hospital sued Eli Lilly over allegedly pulling 340B discounts, creating a legal/regulatory overhang that could pressure sentiment if the dispute escalates. Healthcare Finance News article

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LLY. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research report on Monday. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a report on Wednesday. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,263.41.

Eli Lilly and Company Stock Performance

The company has a market capitalization of $1.12 trillion, a PE ratio of 42.24, a PEG ratio of 1.51 and a beta of 0.51. The firm has a 50-day moving average of $1,091.91 and a two-hundred day moving average of $1,032.43. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 35.81 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $25,000. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares during the period. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $30,000. Finally, Maseco LLP lifted its position in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.